|
AU2728588A
(en)
|
1987-10-23 |
1989-05-23 |
Genetics Institute Inc. |
Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
EP0955365A3
(en)
|
1992-06-09 |
2000-12-20 |
Chiron Corporation |
Crystallization of M-CSF
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU1804499A
(en)
|
1997-12-05 |
1999-06-28 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
CA2348292A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparation
|
|
JP4307775B2
(ja)
|
1999-10-28 |
2009-08-05 |
ゼイェトホサイン・アハリネヤート |
Ｃｓｆ−１インヒビターの使用
|
|
AU1759501A
(en)
|
1999-11-08 |
2001-06-06 |
Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
AU2002329540A1
(en)
|
2001-06-20 |
2003-01-02 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
US7807389B2
(en)
|
2003-03-14 |
2010-10-05 |
University Of Rochester |
Methods and compositions related to joint inflammation diseases
|
|
JP4810427B2
(ja)
|
2003-05-22 |
2011-11-09 |
アボット・ラボラトリーズ |
インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
JP2007524671A
(ja)
|
2004-01-21 |
2007-08-30 |
カイロン コーポレイション |
Ｍ−ｃｓｆムテインおよびその使用
|
|
JP2008506366A
(ja)
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
EP2479277B1
(en)
|
2004-07-22 |
2015-09-02 |
Five Prime Therapeutics, Inc. |
Use of MGD-CSF in a method of treatment of Alzheimer's disease.
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN101384621A
(zh)
|
2005-11-10 |
2009-03-11 |
受体生物公司 |
产生受体和配体同种型的方法
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
CN101379400A
(zh)
|
2005-12-22 |
2009-03-04 |
诺华有限公司 |
可溶性人m-csf受体及其应用
|
|
AU2007205048B2
(en)
|
2006-01-05 |
2013-07-04 |
Novartis Ag |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
CA2669599A1
(en)
|
2006-11-17 |
2008-05-22 |
Biogen Idec Ma Inc. |
Systemic administration of colony stimulating factors to treat amyloid associated disorders
|
|
US7919594B2
(en)
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
WO2008150383A1
(en)
|
2007-05-30 |
2008-12-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Csf-1r mutants
|
|
ES2650224T3
(es)
|
2007-08-21 |
2018-01-17 |
Amgen, Inc. |
Proteínas de unión al antígeno C-FMS humano
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
CA2704231A1
(en)
|
2007-10-31 |
2009-05-07 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to fms treatment
|
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
DK2262836T3
(da)
|
2008-03-14 |
2016-04-04 |
Transgene Sa |
Antistof mod CSF-1R
|
|
JP2011519868A
(ja)
|
2008-05-05 |
2011-07-14 |
シェーリング コーポレイション |
癌を処置するための化学療法剤の連続投与
|
|
US8460886B2
(en)
|
2008-07-04 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
WO2010062401A2
(en)
|
2008-11-26 |
2010-06-03 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
MX378336B
(es)
|
2010-05-04 |
2025-03-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
TW201307845A
(zh)
|
2010-12-13 |
2013-02-16 |
Novartis Ag |
預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
US9139652B2
(en)
|
2011-10-21 |
2015-09-22 |
Transgene Sa |
Method for increasing M1 macrophages in a patient
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
US20170037125A1
(en)
*
|
2014-02-04 |
2017-02-09 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
PT3212670T
(pt)
*
|
2014-10-29 |
2021-02-15 |
Bristol Myers Squibb Co |
Terapêutica de combinação para cancro
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
JOP20190055A1
(ar)
*
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
AU2017339517B2
(en)
*
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
KR102922386B1
(ko)
*
|
2017-07-21 |
2026-02-04 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|